
    
      This multicenter study is open. No vaccine will be administered during this persistence phase
      of the study. The subjects were randomized in the primary vaccination study 217744/097
      (DTPa-HBV-IPV-097) and will not be further randomized in this study. The study has 3 groups
      with Meningitec™ primed group as control. The protocol was amended to allow for enrollment of
      subjects of the Meningitec™ primed control group who were boosted with Meningitec™ after the
      end of the booster study as per new local reccommendation in Spain.
    
  